Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 1.00 |
| ▸ | CA1 | P00915 | 14/20 | 1.00 |
| ▸ | CA9 | Q16790 | 14/20 | 1.00 |
| ▸ | CA12 | O43570 | 8/20 | 1.00 |
| ▸ | CA4 | P22748 | 6/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 1.00 |
| ▸ | CA6 | P23280 | 5/20 | 1.00 |
| ▸ | CA5A | P35218 | 5/20 | 1.00 |
| ▸ | CA7 | P43166 | 5/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30351262 | 1.00 | CA2 (1.00) | CA2CA1CA9CA12CA4 | |
| SCHEMBL2811342 | 0.86 | CA2 (0.76) | CA2CA1CA9CA12CA4 | |
| SCHEMBL29948313 | 0.83 | CA2 (0.70) | CA2CA1CA9CA12CA4 | |
| SCHEMBL7769757 | 0.83 | CA2 (0.70) | CA2CA1CA9CA12CA4 | |
| SCHEMBL3434572 | 0.83 | CA2 (0.70) | CA2CA1CA9CA12CA4 | |
| SCHEMBL8492996 | 0.83 | CA2 (0.70) | CA2CA1CA9CA12CA4 | |
| SCHEMBL10694524 | 0.83 | CA2 (0.70) | CA2CA1CA9CA12CA4 | |
| SCHEMBL4603717 | 0.82 | CA2 (0.69) | CA2CA1CA9CA12CA4 | |
| SCHEMBL11335889 | 0.82 | CA2 (0.67) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1911572 | 0.81 | PKM (0.87) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-23 | — | — | US | disclosed |
| EP-4423081-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118201920-A | PAPD5 inhibitors and methods of use thereof | 儿童医疗中心公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-106146358-B | Method for synthesizing amino- (N-alkyl) benzene sulfonamide | 南京理工大学 | 2018-01-23 | — | — | CN | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| CN-106146358-A | Method for synthesizing amino- (N-alkyl) benzene sulfonamide | 南京理工大学 | 2016-11-23 | — | — | CN | disclosed |
| EP-2594265-B1 | Ca ix-specific inhibitors | INST VIROLOGY (SK) | 2015-10-28 | — | — | EP | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1940781-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7388111-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080095707-A1 | CA IX-SPECIFIC INHIBITORS | INSTITUTE OF VIROLOGY SLOVAK ACADEMY OF SCIENCES (SK) | 2008-04-24 | — | — | US | disclosed |
| WO-2008009613-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-01-24 | — | — | US | disclosed |
| WO-2007045573-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088053-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
| CN-1269813-C | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| CN-1452620-A | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (CH) | 2003-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | CA2 849/4885CA1 2506/4885CA9 1284/4885 |
| US-20080095707-A1 | CA IX-SPECIFIC INHIBITORS | CA9, CA6, CA14 | CA2 5/4885CA1 4/4885CA9 1/4885 |
| US-20070088053-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, RTF1 | CA2 4750/4885CA1 4746/4885CA9 4603/4885 |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | CA2 849/4885CA1 2506/4885CA9 1284/4885 |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | CA2 4661/4885CA1 4584/4885CA9 3964/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | CA2 1212/4885CA1 3222/4885CA9 1830/4885 |
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, HPRT1, NQO2 | CA2 4383/4885CA1 4554/4885CA9 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.